Orally Disintegrating Tablet Market Size, Share, and Growth Forecast for 2025 - 2032

Orally Disintegrating Tablet Market Size and Trends

The global orally disintegrating tablet market size is anticipated to reach a value of US$ 25,082.1 Mn in 2025 and is set to witness a CAGR of 8.5% from 2025 to 2032. The market will likely attain a value of US$ 48,186.8 Mn in 2032.

The oral route of drug administration is the usual approach in the pharmaceutical business since it is the most cost-effective, easier, and safer way of drug administration. The tablets are normally taken with water.

The oral tablets enter the gastrointestinal tract and are immediately absorbed into the bloodstream. However, the orally disintegrating tablets are solid dosage forms that quickly dissolve in the mouth and do not require water to ingest. Orally disintegrating tablets are increasingly being used as an alternative to traditional tablets or capsules.

Key Highlights of the Orally Disintegrating Tablet Industry

• North America is estimated to hold a share of 39.2% in 2025 presence of well-established pharmaceutical companies, advanced healthcare infrastructure, and high healthcare expenditures.
• Anti-Psychotic Drugs segment by drug class will likely generate 19.7% share in 2025 due to crucial role in managing schizophrenia, bipolar disorder, and other psychiatric conditions where patient compliance is a major concern
• Based on Disease Indication, Central Nervous System (CNS) are likely to grow due to the high prevalence of neurological conditions like epilepsy, Parkinson's disease, and migraines, which often require rapid-onset medications for acute symptom management.
• The rising incidence of neurological disorders, gastrointestinal issues, and cardiovascular diseases is driving demand for ODTs, as they provide an easy-to-administer alternative, improving medication adherence among elderly, pediatric, and dysphagic patients, thus fueling global market expansion.
• Innovations such as taste-masking, rapid-dissolution, and bioavailability enhancement techniques are making ODTs more effective and patient-friendly. These advancements, coupled with growing investments in pharmaceutical R&D, are significantly boosting the adoption of ODTs worldwide, especially in emerging healthcare markets.

Global Market Attributes	Key Insights
Orally Disintegrating Tablet Market Size (2025E)	US$ 25,082.1 Mn
Market Value Forecast (2032F)	US$ 48,186.8 Mn
Projected Growth (CAGR 2025 to 2032)	8.5%
Historical Market Growth (CAGR 2019 to 2024)	7.8%

Historical Growth and Course Ahead

In the historical period from 2019 to 2024, the global orally disintegrating tablet industry witnessed a CAGR of 7.8%.

The market is likely to have a CAGR of 8.5% over the forecast period. One of the primary factors driving the growth of Orally Disintegrating Tablets is that these tablets are increasingly being used as an alternative to traditional tablets or capsules. Apart from this, the rising adoption of technologically improved products and an increase in the prevalence of CNS illnesses such as depression, migraine, Parkinson's disease, Alzheimer's disease, and schizophrenia are likely to drive market growth.

Market Dynamics

Growth Drivers

Increased Adoption of Orally Disintegrating Tablet

Because of improved patient compliance, orally disintegrating tablets (ODTs) are being increasingly adopted over the last few years as a preferable substitute for traditional tablets and capsules. Orally disintegrating tablets dissolve in the mouth within minutes and do not require water to ingest. Traditional medications are difficult to swallow for infants, young children, and elderly people. To address such complications, various orally disintegrating pills with increased performance are developed and launched. Furthermore, advancements like enhanced taste and disintegration are enhancing ODT adoption.

Market Restraining Factors

Limited drug load capacity

One of the significant restraints in the growth of the orally disintegrating tablet (ODT) market is the limited drug load capacity. ODTs are specifically designed to disintegrate quickly in the mouth without the need for water, which requires them to be smaller in size and formulated with rapidly dissolving excipients. However, this structural constraint poses a challenge when incorporating higher doses of active pharmaceutical ingredients (APIs). As a result, ODTs are typically restricted to medications with lower dosage requirements, limiting their applicability for drugs that necessitate higher concentrations for therapeutic efficacy.

For instance, Adare Pharma Solutions’ Advatabs technology supports drug loading of up to 500 mg, which, while higher than many traditional ODTs, still falls short for certain high-dose medications.

Orally Disintegrating Tablet Market Insights and Trends

Drug Class Insights

Market Dominance of Anti-Psychotic Drugs in the Orally Disintegrating Tablet (ODT) Segment

Anti-psychotic drugs are leading the drug class category in the orally disintegrating tablet (ODT) market projected to hold 19.7% of market share in 2025, due to their crucial role in managing schizophrenia, bipolar disorder, and other psychiatric conditions where patient compliance is a major concern. Many patients with these disorders struggle with swallowing pills or may be non-adherent to treatment, making ODTs a preferred option as they dissolve quickly without water. Additionally, the rapid onset of action in ODT formulations is beneficial for managing acute psychiatric episodes. Major pharmaceutical companies have also focused on developing ODT versions of widely prescribed antipsychotics, further driving market growth.

Disease Indication Insights

CNS Disorders Driving Growth in the Orally Disintegrating Tablet (ODT) Market

Central Nervous System (CNS) diseases dominate the market and is projected to hold 56.7% of market share in 2025, over gastrointestinal (GI) diseases, cardiovascular system (CVS) disorders, allergies, and other Disease Indication. This is primarily due to the high prevalence of neurological conditions like epilepsy, Parkinson's disease, and migraines, which often require rapid-onset medications for acute symptom management. ODTs offer a convenient administration route for patients with dysphagia or difficulty swallowing, common among individuals with CNS disorders, enhancing compliance and therapeutic outcomes.

In February 2020, Rimegepant, an ODT for acute migraine treatment, demonstrated efficacy in reducing symptoms within two hours, offering a rapid-onset option for migraine sufferers. Additionally, the development of ODT formulations for antipsychotic and antiepileptic drugs has further driven adoption in CNS treatment.

Regional Insights and Trends

North America Orally Disintegrating Tablet Market

North America Dominates the Market with Strong Growth Prospects

North America leads the market with 39.2% of share in 2025, driven by the presence of well-established pharmaceutical companies, advanced healthcare infrastructure, and high healthcare expenditures. The region is projected to retain its dominance over the forecast period, primarily fueled by the rising prevalence of chronic diseases.

According to data published by the Centers for Disease Control and Prevention (CDC) on October 10, 2023, six out of ten U.S. adults suffer from chronic illnesses such as heart disease, cancer, or diabetes. Notably, heart disease and cancer alone account for approximately 38% of all deaths in the country.

Europe Orally Disintegrating Tablet Market

Europe Emerges as the Fastest-Growing Region

Europe is the fastest-growing region in the market with 29.1% share in 2025, due to favorable reimbursement policies, a well-developed healthcare system, and a high prevalence of chronic diseases. The presence of key pharmaceutical manufacturers and continuous investments in research and development activities contribute to growth of the orodispersible tablets market in Europe.

For Instance, In December 2024, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Leqembi for treating early-stage Alzheimer's disease. This decision came after a previous rejection due to safety concerns, marking a significant advancement in Alzheimer's treatment within the European Union.

South Asia Orally Disintegrating Tablet Market

South Asia and Oceania Lead Orally Disintegrating Tablet Market Growth, with India Emerging as a Key Country

South Asia and Oceania are witnessing rapid growth in the market, driven by multiple factors. The rising prevalence of chronic diseases has increased the need for easily accessible medications, with ODTs offering a convenient solution, particularly for individuals with swallowing difficulties. The expanding geriatric population further fuels demand for these formulations.

Advancements in pharmaceutical technology, improved healthcare infrastructure, and frequent new product launches contribute to market growth.  For example, In March 2023, Zydus Lifesciences received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg (USRLD: Zyprexa Zydis Orally Disintegrating Tablets).

Orally Disintegrating Tablet Market Competitive Landscape

The market is moderately competitive due to the presence of small and large market players who offer a range of orally disintegrating tablets. The market players are actively involved in enhancing their offering to increase their market share.

Key Industry Developments

• In July 2024, Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is an Orally Disintegrating Tablet (ODT).
• In March 2024, Dr. Reddy’s Laboratories Ltd. announced that it had received approval from the Central Drugs Standard Control Organization (CDSCO) for the manufacturing and marketing of Omeprazole delayed-release orally disintegrating tablets in the Indian market.

Companies Covered in Orally Disintegrating Tablet Market

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• AstraZeneca
• Mylan N.V.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Bausch Health
• GlaxoSmithKline plc.
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Eli Lily and Company
• Dr. Reddy’s Laboratories Ltd.
• Takeda Pharmaceutical Company Limited
• Catalent Pharma Solutions
• Neos Therapeutics
• Eisai Co.
• Zydus Lifesciences
• Aurobindo Pharma
• Torrent Pharmaceuticals